US Bancorp DE Increases Position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

US Bancorp DE grew its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 213.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,365 shares of the company's stock after acquiring an additional 12,500 shares during the period. US Bancorp DE's holdings in Zai Lab were worth $664,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of ZLAB. GF Fund Management CO. LTD. acquired a new position in shares of Zai Lab in the fourth quarter worth $29,000. Barclays PLC grew its stake in shares of Zai Lab by 337.6% during the fourth quarter. Barclays PLC now owns 3,702 shares of the company's stock worth $97,000 after purchasing an additional 2,856 shares in the last quarter. Advisors Preferred LLC acquired a new position in shares of Zai Lab during the first quarter worth $110,000. Palumbo Wealth Management LLC acquired a new position in shares of Zai Lab during the first quarter worth $203,000. Finally, Jasper Ridge Partners L.P. acquired a new position in shares of Zai Lab during the fourth quarter worth $210,000. Institutional investors and hedge funds own 41.65% of the company's stock.

Insider Activity at Zai Lab

In other news, CEO Ying Du sold 50,000 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $34.74, for a total value of $1,737,000.00. Following the completion of the sale, the chief executive officer directly owned 536,962 shares of the company's stock, valued at approximately $18,654,059.88. This represents a 8.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William Lis sold 13,814 shares of the company's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $35.67, for a total transaction of $492,745.38. Following the completion of the sale, the director directly owned 35,106 shares of the company's stock, valued at $1,252,231.02. The trade was a 28.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 217,249 shares of company stock worth $7,586,620. Insiders own 4.96% of the company's stock.

Zai Lab Stock Performance

NASDAQ ZLAB traded up $0.81 during trading hours on Friday, hitting $35.74. The company had a trading volume of 46,804 shares, compared to its average volume of 981,906. Zai Lab Limited Unsponsored ADR has a 1-year low of $16.41 and a 1-year high of $44.34. The company has a market cap of $3.97 billion, a PE ratio of -17.57 and a beta of 1.03. The business has a 50 day moving average of $36.73 and a 200-day moving average of $33.44.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.37). Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. The company had revenue of $109.98 million during the quarter, compared to the consensus estimate of $125.66 million. Sell-side analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

ZLAB has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Citigroup reiterated a "buy" rating and set a $69.00 target price (up previously from $66.00) on shares of Zai Lab in a research note on Monday. Finally, Leerink Partners set a $75.00 target price on shares of Zai Lab and gave the stock an "outperform" rating in a research note on Monday, June 30th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Zai Lab currently has a consensus rating of "Moderate Buy" and an average price target of $57.22.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.